Nuveen
TSHA icon

Nuveen’s Taysha Gene Therapies TSHA Stock Holding History

Nuveen’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.78M Buy
555,693
+6,540
+1% +$38.7K ﹤0.01% 2250
2026
Q1 		$2.45M Buy
549,153
+3,867
+0.7% +$18K ﹤0.01% 2195
2025
Q4 		$3M Buy
545,286
+38,076
+8% +$185K ﹤0.01% 2132
2025
Q3 		$1.66M Buy
507,210
+42,066
+9% +$119K ﹤0.01% 2372
2025
Q2 		$1.07M Sell
465,144
-81,270
-15% -$177K ﹤0.01% 2569
2025
Q1 		$760K Hold
546,414
– – ﹤0.01% 2753
2024
Q4 		$945K Sell
546,414
-20,436
-4% -$42.4K ﹤0.01% 2736
2024
Q3 		$1.14M Sell
566,850
-512,249
-47% -$1.12M ﹤0.01% 2699
2024
Q2 		$2.42M Buy
+1,079,099
New +$3.14M ﹤0.01% 2290
2022
Q2 		– Sell
-105,426
Closed -$665K – 3479
2022
Q1 		$665K Buy
105,426
+2,858
+3% +$21.4K ﹤0.01% 2931
2021
Q4 		$1.2M Buy
102,568
+10,194
+11% +$154K ﹤0.01% 2796
2021
Q3 		$1.72M Buy
92,374
+11,952
+15% +$227K ﹤0.01% 2741
2021
Q2 		$1.71M Buy
80,422
+62,821
+357% +$1.45M ﹤0.01% 2785
2021
Q1 		$357K Buy
17,601
+3,373
+24% +$91.3K ﹤0.01% 3146
2020
Q4 		$378K Buy
+14,228
New +$307K ﹤0.01% 3100

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nuveen's TSHA Position: Q2 2026 in Review

Nuveen increased its Taysha Gene Therapies (TSHA) stake by 1.2% in Q2 2026, buying an estimated $38.7K and bringing the position to 555,693 shares worth $3.78M. The position accounts for ﹤0.01% of the portfolio, ranked #2250.

Nuveen first reported a position in TSHA in Q4 2020 and has held it in 15 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Nuveen held 555,693 shares of Taysha Gene Therapies worth $3.78M as of Q2 2026.
  • Nuveen bought 6,540 Taysha Gene Therapies shares in Q2 2026, an estimated $38.7K.
  • Taysha Gene Therapies made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2250 holding.
  • Nuveen first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 15 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.